Agilent Technologies, Inc.
Agilent Technologies, Inc. (A) Stock Competitors & Peer Comparison
See (A) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| A | $111.51 | -0.10% | 31.5B | 24.67 | $4.52 | +0.89% |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.68% |
| TMO | $464.37 | -2.42% | 172.5B | 26.16 | $17.75 | +0.38% |
| DHR | $187.32 | +0.57% | 132.5B | 37.18 | $5.04 | +0.68% |
| IDXX | $573.82 | +0.46% | 45.8B | 43.97 | $13.05 | N/A |
| IQV | $164.72 | +1.10% | 27.9B | 21.01 | $7.84 | N/A |
| NTRA | $187.85 | -1.29% | 26.6B | -123.59 | -$1.52 | N/A |
| MTD | $1,173.74 | +0.49% | 24B | 27.91 | $42.05 | N/A |
| DGX | $199.70 | -0.59% | 22.2B | 22.84 | $8.74 | +1.60% |
| LH | $263.80 | +0.34% | 21.9B | 25.20 | $10.47 | +1.09% |
Stock Comparison
A vs DHR-PB Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, A is priced at $111.51, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, A's ROE is +0.20%, compared to DHR-PB's ROE of +0.07%. Regarding short-term risk, A is more volatile compared to DHR-PB. This indicates potentially higher risk in terms of short-term price fluctuations for A.Check DHR-PB's competition here
A vs TMO Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, TMO has a market cap of 172.5B. Regarding current trading prices, A is priced at $111.51, while TMO trades at $464.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas TMO's P/E ratio is 26.16. In terms of profitability, A's ROE is +0.20%, compared to TMO's ROE of +0.13%. Regarding short-term risk, A is less volatile compared to TMO. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check TMO's competition here
A vs DHR Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, DHR has a market cap of 132.5B. Regarding current trading prices, A is priced at $111.51, while DHR trades at $187.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas DHR's P/E ratio is 37.18. In terms of profitability, A's ROE is +0.20%, compared to DHR's ROE of +0.07%. Regarding short-term risk, A is more volatile compared to DHR. This indicates potentially higher risk in terms of short-term price fluctuations for A.Check DHR's competition here
A vs IDXX Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, IDXX has a market cap of 45.8B. Regarding current trading prices, A is priced at $111.51, while IDXX trades at $573.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas IDXX's P/E ratio is 43.97. In terms of profitability, A's ROE is +0.20%, compared to IDXX's ROE of +0.70%. Regarding short-term risk, A is more volatile compared to IDXX. This indicates potentially higher risk in terms of short-term price fluctuations for A.Check IDXX's competition here
A vs IQV Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, IQV has a market cap of 27.9B. Regarding current trading prices, A is priced at $111.51, while IQV trades at $164.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas IQV's P/E ratio is 21.01. In terms of profitability, A's ROE is +0.20%, compared to IQV's ROE of +0.22%. Regarding short-term risk, A is more volatile compared to IQV. This indicates potentially higher risk in terms of short-term price fluctuations for A.Check IQV's competition here
A vs NTRA Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, NTRA has a market cap of 26.6B. Regarding current trading prices, A is priced at $111.51, while NTRA trades at $187.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas NTRA's P/E ratio is -123.59. In terms of profitability, A's ROE is +0.20%, compared to NTRA's ROE of -0.15%. Regarding short-term risk, A is less volatile compared to NTRA. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check NTRA's competition here
A vs MTD Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, MTD has a market cap of 24B. Regarding current trading prices, A is priced at $111.51, while MTD trades at $1,173.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas MTD's P/E ratio is 27.91. In terms of profitability, A's ROE is +0.20%, compared to MTD's ROE of -4.87%. Regarding short-term risk, A is more volatile compared to MTD. This indicates potentially higher risk in terms of short-term price fluctuations for A.Check MTD's competition here
A vs DGX Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, DGX has a market cap of 22.2B. Regarding current trading prices, A is priced at $111.51, while DGX trades at $199.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas DGX's P/E ratio is 22.84. In terms of profitability, A's ROE is +0.20%, compared to DGX's ROE of +0.14%. Regarding short-term risk, A is less volatile compared to DGX. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check DGX's competition here
A vs LH Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, LH has a market cap of 21.9B. Regarding current trading prices, A is priced at $111.51, while LH trades at $263.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas LH's P/E ratio is 25.20. In terms of profitability, A's ROE is +0.20%, compared to LH's ROE of +0.10%. Regarding short-term risk, A is more volatile compared to LH. This indicates potentially higher risk in terms of short-term price fluctuations for A.Check LH's competition here
A vs EXAS Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, EXAS has a market cap of 19.8B. Regarding current trading prices, A is priced at $111.51, while EXAS trades at $103.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas EXAS's P/E ratio is -94.15. In terms of profitability, A's ROE is +0.20%, compared to EXAS's ROE of -0.09%. Regarding short-term risk, A is more volatile compared to EXAS. This indicates potentially higher risk in terms of short-term price fluctuations for A.Check EXAS's competition here
A vs ILMN Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, ILMN has a market cap of 18.2B. Regarding current trading prices, A is priced at $111.51, while ILMN trades at $118.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas ILMN's P/E ratio is 21.78. In terms of profitability, A's ROE is +0.20%, compared to ILMN's ROE of +0.35%. Regarding short-term risk, A is less volatile compared to ILMN. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check ILMN's competition here
A vs WAT Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, WAT has a market cap of 17B. Regarding current trading prices, A is priced at $111.51, while WAT trades at $286.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas WAT's P/E ratio is 26.60. In terms of profitability, A's ROE is +0.20%, compared to WAT's ROE of +0.29%. Regarding short-term risk, A is more volatile compared to WAT. This indicates potentially higher risk in terms of short-term price fluctuations for A.Check WAT's competition here
A vs PKI Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, A is priced at $111.51, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas PKI's P/E ratio is 41.45. In terms of profitability, A's ROE is +0.20%, compared to PKI's ROE of +0.03%. Regarding short-term risk, A is more volatile compared to PKI. This indicates potentially higher risk in terms of short-term price fluctuations for A.Check PKI's competition here
A vs MEDP Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, MEDP has a market cap of 12.8B. Regarding current trading prices, A is priced at $111.51, while MEDP trades at $450.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas MEDP's P/E ratio is 29.46. In terms of profitability, A's ROE is +0.20%, compared to MEDP's ROE of +1.19%. Regarding short-term risk, A is less volatile compared to MEDP. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check MEDP's competition here
A vs GH Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, GH has a market cap of 11.2B. Regarding current trading prices, A is priced at $111.51, while GH trades at $85.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas GH's P/E ratio is -25.75. In terms of profitability, A's ROE is +0.20%, compared to GH's ROE of +1.65%. Regarding short-term risk, A is less volatile compared to GH. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check GH's competition here
A vs RVTY Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, RVTY has a market cap of 9.7B. Regarding current trading prices, A is priced at $111.51, while RVTY trades at $85.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas RVTY's P/E ratio is 41.95. In terms of profitability, A's ROE is +0.20%, compared to RVTY's ROE of +0.03%. Regarding short-term risk, A is less volatile compared to RVTY. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check RVTY's competition here
A vs QGEN Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, QGEN has a market cap of 8.4B. Regarding current trading prices, A is priced at $111.51, while QGEN trades at $40.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas QGEN's P/E ratio is 19.90. In terms of profitability, A's ROE is +0.20%, compared to QGEN's ROE of +0.12%. Regarding short-term risk, A is less volatile compared to QGEN. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check QGEN's competition here
A vs CRL Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, CRL has a market cap of 7.7B. Regarding current trading prices, A is priced at $111.51, while CRL trades at $155.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas CRL's P/E ratio is -53.48. In terms of profitability, A's ROE is +0.20%, compared to CRL's ROE of -0.04%. Regarding short-term risk, A is less volatile compared to CRL. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check CRL's competition here
A vs ICLR Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, ICLR has a market cap of 7.5B. Regarding current trading prices, A is priced at $111.51, while ICLR trades at $98.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas ICLR's P/E ratio is 13.25. In terms of profitability, A's ROE is +0.20%, compared to ICLR's ROE of +0.06%. Regarding short-term risk, A is less volatile compared to ICLR. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check ICLR's competition here
A vs RDNT Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, RDNT has a market cap of 4.8B. Regarding current trading prices, A is priced at $111.51, while RDNT trades at $62.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas RDNT's P/E ratio is -388.06. In terms of profitability, A's ROE is +0.20%, compared to RDNT's ROE of -0.02%. Regarding short-term risk, A is less volatile compared to RDNT. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check RDNT's competition here
A vs SYNH Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, A is priced at $111.51, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas SYNH's P/E ratio is 61.40. In terms of profitability, A's ROE is +0.20%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, A is more volatile compared to SYNH. This indicates potentially higher risk in terms of short-term price fluctuations for A.Check SYNH's competition here
A vs SHC Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, SHC has a market cap of 3.8B. Regarding current trading prices, A is priced at $111.51, while SHC trades at $13.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas SHC's P/E ratio is 49.69. In terms of profitability, A's ROE is +0.20%, compared to SHC's ROE of +0.15%. Regarding short-term risk, A is less volatile compared to SHC. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check SHC's competition here
A vs OLK Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, A is priced at $111.51, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas OLK's P/E ratio is -96.59. In terms of profitability, A's ROE is +0.20%, compared to OLK's ROE of -0.07%. Regarding short-term risk, A is more volatile compared to OLK. This indicates potentially higher risk in terms of short-term price fluctuations for A.Check OLK's competition here
A vs BLLN Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, BLLN has a market cap of 3.2B. Regarding current trading prices, A is priced at $111.51, while BLLN trades at $69.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas BLLN's P/E ratio is 493.64. In terms of profitability, A's ROE is +0.20%, compared to BLLN's ROE of +0.01%. Regarding short-term risk, A is less volatile compared to BLLN. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check BLLN's competition here
A vs TWST Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, TWST has a market cap of 2.7B. Regarding current trading prices, A is priced at $111.51, while TWST trades at $43.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas TWST's P/E ratio is -34.08. In terms of profitability, A's ROE is +0.20%, compared to TWST's ROE of -0.17%. Regarding short-term risk, A is less volatile compared to TWST. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check TWST's competition here
A vs NEOG Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, NEOG has a market cap of 2B. Regarding current trading prices, A is priced at $111.51, while NEOG trades at $9.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas NEOG's P/E ratio is -3.27. In terms of profitability, A's ROE is +0.20%, compared to NEOG's ROE of -0.27%. Regarding short-term risk, A is less volatile compared to NEOG. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check NEOG's competition here
A vs GRAL Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, GRAL has a market cap of 1.7B. Regarding current trading prices, A is priced at $111.51, while GRAL trades at $43.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas GRAL's P/E ratio is -3.88. In terms of profitability, A's ROE is +0.20%, compared to GRAL's ROE of -0.17%. Regarding short-term risk, A is less volatile compared to GRAL. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check GRAL's competition here
A vs VIVO Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, VIVO has a market cap of 1.5B. Regarding current trading prices, A is priced at $111.51, while VIVO trades at $33.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas VIVO's P/E ratio is 21.09. In terms of profitability, A's ROE is +0.20%, compared to VIVO's ROE of +0.12%. Regarding short-term risk, A is more volatile compared to VIVO. This indicates potentially higher risk in terms of short-term price fluctuations for A.Check VIVO's competition here
A vs OPK Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, OPK has a market cap of 913.6M. Regarding current trading prices, A is priced at $111.51, while OPK trades at $1.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas OPK's P/E ratio is -3.97. In terms of profitability, A's ROE is +0.20%, compared to OPK's ROE of -0.17%. Regarding short-term risk, A is less volatile compared to OPK. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check OPK's competition here
A vs CDNA Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, CDNA has a market cap of 874.9M. Regarding current trading prices, A is priced at $111.51, while CDNA trades at $17.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas CDNA's P/E ratio is -42.52. In terms of profitability, A's ROE is +0.20%, compared to CDNA's ROE of -0.06%. Regarding short-term risk, A is less volatile compared to CDNA. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check CDNA's competition here
A vs CSTL Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, CSTL has a market cap of 759.9M. Regarding current trading prices, A is priced at $111.51, while CSTL trades at $25.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas CSTL's P/E ratio is -30.80. In terms of profitability, A's ROE is +0.20%, compared to CSTL's ROE of -0.05%. Regarding short-term risk, A is less volatile compared to CSTL. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check CSTL's competition here
A vs PSNL Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, PSNL has a market cap of 596.8M. Regarding current trading prices, A is priced at $111.51, while PSNL trades at $6.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas PSNL's P/E ratio is -7.38. In terms of profitability, A's ROE is +0.20%, compared to PSNL's ROE of -0.39%. Regarding short-term risk, A is less volatile compared to PSNL. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check PSNL's competition here
A vs GRALV Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, A is priced at $111.51, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas GRALV's P/E ratio is N/A. In terms of profitability, A's ROE is +0.20%, compared to GRALV's ROE of N/A. Regarding short-term risk, A is less volatile compared to GRALV. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check GRALV's competition here
A vs FLGT Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, FLGT has a market cap of 461.3M. Regarding current trading prices, A is priced at $111.51, while FLGT trades at $14.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas FLGT's P/E ratio is -7.50. In terms of profitability, A's ROE is +0.20%, compared to FLGT's ROE of -0.05%. Regarding short-term risk, A is less volatile compared to FLGT. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check FLGT's competition here
A vs MYGN Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, MYGN has a market cap of 435.7M. Regarding current trading prices, A is priced at $111.51, while MYGN trades at $4.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas MYGN's P/E ratio is -1.18. In terms of profitability, A's ROE is +0.20%, compared to MYGN's ROE of -0.80%. Regarding short-term risk, A is less volatile compared to MYGN. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check MYGN's competition here
A vs ACRS Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, ACRS has a market cap of 426.9M. Regarding current trading prices, A is priced at $111.51, while ACRS trades at $3.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas ACRS's P/E ratio is -6.68. In terms of profitability, A's ROE is +0.20%, compared to ACRS's ROE of -0.52%. Regarding short-term risk, A is less volatile compared to ACRS. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check ACRS's competition here
A vs CO Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, A is priced at $111.51, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas CO's P/E ratio is 5.06. In terms of profitability, A's ROE is +0.20%, compared to CO's ROE of +0.11%. Regarding short-term risk, A is less volatile compared to CO. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check CO's competition here
A vs ATLN Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, ATLN has a market cap of 297M. Regarding current trading prices, A is priced at $111.51, while ATLN trades at $4.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas ATLN's P/E ratio is -1.87. In terms of profitability, A's ROE is +0.20%, compared to ATLN's ROE of +6.06%. Regarding short-term risk, A is less volatile compared to ATLN. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check ATLN's competition here
A vs FLDM Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, A is priced at $111.51, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas FLDM's P/E ratio is -4.74. In terms of profitability, A's ROE is +0.20%, compared to FLDM's ROE of -0.18%. Regarding short-term risk, A is less volatile compared to FLDM. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check FLDM's competition here
A vs PRE Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, PRE has a market cap of 291.2M. Regarding current trading prices, A is priced at $111.51, while PRE trades at $20.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas PRE's P/E ratio is -5.47. In terms of profitability, A's ROE is +0.20%, compared to PRE's ROE of -0.36%. Regarding short-term risk, A is less volatile compared to PRE. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check PRE's competition here
A vs OPGN Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, OPGN has a market cap of 251.2M. Regarding current trading prices, A is priced at $111.51, while OPGN trades at $24.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas OPGN's P/E ratio is 137.50. In terms of profitability, A's ROE is +0.20%, compared to OPGN's ROE of +0.78%. Regarding short-term risk, A is less volatile compared to OPGN. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check OPGN's competition here
A vs NEO Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, NEO has a market cap of 204.6M. Regarding current trading prices, A is priced at $111.51, while NEO trades at $7.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas NEO's P/E ratio is -9.38. In terms of profitability, A's ROE is +0.20%, compared to NEO's ROE of -0.13%. Regarding short-term risk, A is less volatile compared to NEO. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check NEO's competition here
A vs MDXH Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, MDXH has a market cap of 164.4M. Regarding current trading prices, A is priced at $111.51, while MDXH trades at $3.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas MDXH's P/E ratio is -4.78. In terms of profitability, A's ROE is +0.20%, compared to MDXH's ROE of +5.17%. Regarding short-term risk, A is less volatile compared to MDXH. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check MDXH's competition here
A vs BDSX Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, BDSX has a market cap of 135M. Regarding current trading prices, A is priced at $111.51, while BDSX trades at $17.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas BDSX's P/E ratio is -3.83. In terms of profitability, A's ROE is +0.20%, compared to BDSX's ROE of -17.61%. Regarding short-term risk, A is less volatile compared to BDSX. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check BDSX's competition here
A vs GTH Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, A is priced at $111.51, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas GTH's P/E ratio is -1.11. In terms of profitability, A's ROE is +0.20%, compared to GTH's ROE of -1.01%. Regarding short-term risk, A is more volatile compared to GTH. This indicates potentially higher risk in terms of short-term price fluctuations for A.Check GTH's competition here
A vs GENE Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, A is priced at $111.51, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas GENE's P/E ratio is -38.25. In terms of profitability, A's ROE is +0.20%, compared to GENE's ROE of -1.85%. Regarding short-term risk, A is more volatile compared to GENE. This indicates potentially higher risk in terms of short-term price fluctuations for A.Check GENE's competition here
A vs STIM Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, STIM has a market cap of 88.7M. Regarding current trading prices, A is priced at $111.51, while STIM trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas STIM's P/E ratio is -1.56. In terms of profitability, A's ROE is +0.20%, compared to STIM's ROE of -1.51%. Regarding short-term risk, A is less volatile compared to STIM. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check STIM's competition here
A vs SERA Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, SERA has a market cap of 80.1M. Regarding current trading prices, A is priced at $111.51, while SERA trades at $2.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas SERA's P/E ratio is -2.80. In terms of profitability, A's ROE is +0.20%, compared to SERA's ROE of -0.42%. Regarding short-term risk, A is less volatile compared to SERA. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check SERA's competition here
A vs XGN Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, XGN has a market cap of 69.6M. Regarding current trading prices, A is priced at $111.51, while XGN trades at $3.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas XGN's P/E ratio is -3.30. In terms of profitability, A's ROE is +0.20%, compared to XGN's ROE of -1.27%. Regarding short-term risk, A is less volatile compared to XGN. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check XGN's competition here
A vs DRIO Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, DRIO has a market cap of 60.8M. Regarding current trading prices, A is priced at $111.51, while DRIO trades at $9.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas DRIO's P/E ratio is -0.85. In terms of profitability, A's ROE is +0.20%, compared to DRIO's ROE of -0.48%. Regarding short-term risk, A is less volatile compared to DRIO. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check DRIO's competition here
A vs PRPO Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, PRPO has a market cap of 47.1M. Regarding current trading prices, A is priced at $111.51, while PRPO trades at $26.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas PRPO's P/E ratio is -33.16. In terms of profitability, A's ROE is +0.20%, compared to PRPO's ROE of -0.10%. Regarding short-term risk, A is less volatile compared to PRPO. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check PRPO's competition here
A vs STRR Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, STRR has a market cap of 33.2M. Regarding current trading prices, A is priced at $111.51, while STRR trades at $9.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas STRR's P/E ratio is -6.08. In terms of profitability, A's ROE is +0.20%, compared to STRR's ROE of -0.13%. Regarding short-term risk, A is less volatile compared to STRR. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check STRR's competition here
A vs STRRP Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, STRRP has a market cap of 30.7M. Regarding current trading prices, A is priced at $111.51, while STRRP trades at $10.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas STRRP's P/E ratio is -5.04. In terms of profitability, A's ROE is +0.20%, compared to STRRP's ROE of -0.13%. Regarding short-term risk, A is more volatile compared to STRRP. This indicates potentially higher risk in terms of short-term price fluctuations for A.Check STRRP's competition here
A vs AKU Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, A is priced at $111.51, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas AKU's P/E ratio is -0.13. In terms of profitability, A's ROE is +0.20%, compared to AKU's ROE of -5.32%. Regarding short-term risk, A is less volatile compared to AKU. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check AKU's competition here
A vs VNRX Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, VNRX has a market cap of 19M. Regarding current trading prices, A is priced at $111.51, while VNRX trades at $0.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas VNRX's P/E ratio is -0.83. In terms of profitability, A's ROE is +0.20%, compared to VNRX's ROE of +0.77%. Regarding short-term risk, A is less volatile compared to VNRX. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check VNRX's competition here
A vs BNR Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, BNR has a market cap of 18M. Regarding current trading prices, A is priced at $111.51, while BNR trades at $16.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas BNR's P/E ratio is -9.89. In terms of profitability, A's ROE is +0.20%, compared to BNR's ROE of -0.21%. Regarding short-term risk, A is less volatile compared to BNR. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check BNR's competition here
A vs CEMI Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, A is priced at $111.51, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas CEMI's P/E ratio is -0.63. In terms of profitability, A's ROE is +0.20%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, A is more volatile compared to CEMI. This indicates potentially higher risk in terms of short-term price fluctuations for A.Check CEMI's competition here
A vs ENZ Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, A is priced at $111.51, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas ENZ's P/E ratio is -2.24. In terms of profitability, A's ROE is +0.20%, compared to ENZ's ROE of -0.17%. Regarding short-term risk, A is less volatile compared to ENZ. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check ENZ's competition here
A vs PMD Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, A is priced at $111.51, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas PMD's P/E ratio is -5.24. In terms of profitability, A's ROE is +0.20%, compared to PMD's ROE of -0.07%. Regarding short-term risk, A is more volatile compared to PMD. This indicates potentially higher risk in terms of short-term price fluctuations for A.Check PMD's competition here
A vs ME Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, A is priced at $111.51, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas ME's P/E ratio is -0.03. In terms of profitability, A's ROE is +0.20%, compared to ME's ROE of -5.52%. Regarding short-term risk, A is more volatile compared to ME. This indicates potentially higher risk in terms of short-term price fluctuations for A.Check ME's competition here
A vs NOTV Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, NOTV has a market cap of 11.7M. Regarding current trading prices, A is priced at $111.51, while NOTV trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas NOTV's P/E ratio is -0.18. In terms of profitability, A's ROE is +0.20%, compared to NOTV's ROE of -0.51%. Regarding short-term risk, A is less volatile compared to NOTV. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check NOTV's competition here
A vs MBAI Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, MBAI has a market cap of 10.1M. Regarding current trading prices, A is priced at $111.51, while MBAI trades at $1.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas MBAI's P/E ratio is -0.74. In terms of profitability, A's ROE is +0.20%, compared to MBAI's ROE of -2.26%. Regarding short-term risk, A is less volatile compared to MBAI. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check MBAI's competition here
A vs CHEK Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, CHEK has a market cap of 9.8M. Regarding current trading prices, A is priced at $111.51, while CHEK trades at $1.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas CHEK's P/E ratio is -0.39. In terms of profitability, A's ROE is +0.20%, compared to CHEK's ROE of +12.99%. Regarding short-term risk, A is less volatile compared to CHEK. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check CHEK's competition here
A vs BIAF Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, BIAF has a market cap of 9.5M. Regarding current trading prices, A is priced at $111.51, while BIAF trades at $2.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas BIAF's P/E ratio is -0.15. In terms of profitability, A's ROE is +0.20%, compared to BIAF's ROE of -3.81%. Regarding short-term risk, A is less volatile compared to BIAF. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check BIAF's competition here
A vs CNTG Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, A is priced at $111.51, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas CNTG's P/E ratio is -0.23. In terms of profitability, A's ROE is +0.20%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, A is more volatile compared to CNTG. This indicates potentially higher risk in terms of short-term price fluctuations for A.Check CNTG's competition here
A vs TRIB Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, TRIB has a market cap of 7.9M. Regarding current trading prices, A is priced at $111.51, while TRIB trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas TRIB's P/E ratio is -0.48. In terms of profitability, A's ROE is +0.20%, compared to TRIB's ROE of +0.81%. Regarding short-term risk, A is less volatile compared to TRIB. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check TRIB's competition here
A vs APDN Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, A is priced at $111.51, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas APDN's P/E ratio is -0.10. In terms of profitability, A's ROE is +0.20%, compared to APDN's ROE of -8.97%. Regarding short-term risk, A is less volatile compared to APDN. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check APDN's competition here
A vs ADVB Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, ADVB has a market cap of 5.9M. Regarding current trading prices, A is priced at $111.51, while ADVB trades at $5.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas ADVB's P/E ratio is 1.55. In terms of profitability, A's ROE is +0.20%, compared to ADVB's ROE of +1.01%. Regarding short-term risk, A is less volatile compared to ADVB. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check ADVB's competition here
A vs NVTA Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, A is priced at $111.51, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas NVTA's P/E ratio is -0.00. In terms of profitability, A's ROE is +0.20%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, A is less volatile compared to NVTA. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check NVTA's competition here
A vs LMDXW Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, A is priced at $111.51, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, A's ROE is +0.20%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, A is less volatile compared to LMDXW. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check LMDXW's competition here
A vs LMDX Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, A is priced at $111.51, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas LMDX's P/E ratio is -0.01. In terms of profitability, A's ROE is +0.20%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, A is less volatile compared to LMDX. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check LMDX's competition here
A vs BGLC Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, BGLC has a market cap of 4M. Regarding current trading prices, A is priced at $111.51, while BGLC trades at $2.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas BGLC's P/E ratio is -1.73. In terms of profitability, A's ROE is +0.20%, compared to BGLC's ROE of -0.30%. Regarding short-term risk, A is less volatile compared to BGLC. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check BGLC's competition here
A vs BNGO Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, BNGO has a market cap of 3.6M. Regarding current trading prices, A is priced at $111.51, while BNGO trades at $1.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas BNGO's P/E ratio is -0.09. In terms of profitability, A's ROE is +0.20%, compared to BNGO's ROE of -0.86%. Regarding short-term risk, A is less volatile compared to BNGO. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check BNGO's competition here
A vs DMTK Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, A is priced at $111.51, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas DMTK's P/E ratio is -0.04. In terms of profitability, A's ROE is +0.20%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, A is less volatile compared to DMTK. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check DMTK's competition here
A vs MYNZ Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, MYNZ has a market cap of 2.9M. Regarding current trading prices, A is priced at $111.51, while MYNZ trades at $0.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas MYNZ's P/E ratio is -0.13. In terms of profitability, A's ROE is +0.20%, compared to MYNZ's ROE of -4.43%. Regarding short-term risk, A is less volatile compared to MYNZ. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check MYNZ's competition here
A vs NDRA Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, NDRA has a market cap of 2.6M. Regarding current trading prices, A is priced at $111.51, while NDRA trades at $3.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas NDRA's P/E ratio is 0.18. In terms of profitability, A's ROE is +0.20%, compared to NDRA's ROE of -5.38%. Regarding short-term risk, A is less volatile compared to NDRA. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check NDRA's competition here
A vs INBS Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, INBS has a market cap of 2.6M. Regarding current trading prices, A is priced at $111.51, while INBS trades at $4.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas INBS's P/E ratio is -0.28. In terms of profitability, A's ROE is +0.20%, compared to INBS's ROE of -1.98%. Regarding short-term risk, A is less volatile compared to INBS. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check INBS's competition here
A vs SQL Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, A is priced at $111.51, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas SQL's P/E ratio is -0.40. In terms of profitability, A's ROE is +0.20%, compared to SQL's ROE of +9.82%. Regarding short-term risk, A is less volatile compared to SQL. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check SQL's competition here
A vs AWH Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, A is priced at $111.51, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas AWH's P/E ratio is -0.09. In terms of profitability, A's ROE is +0.20%, compared to AWH's ROE of +4.48%. Regarding short-term risk, A is more volatile compared to AWH. This indicates potentially higher risk in terms of short-term price fluctuations for A.Check AWH's competition here
A vs ISPC Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, ISPC has a market cap of 1.6M. Regarding current trading prices, A is priced at $111.51, while ISPC trades at $0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas ISPC's P/E ratio is -0.04. In terms of profitability, A's ROE is +0.20%, compared to ISPC's ROE of -5.32%. Regarding short-term risk, A is less volatile compared to ISPC. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check ISPC's competition here
A vs BIAFW Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, BIAFW has a market cap of 1.5M. Regarding current trading prices, A is priced at $111.51, while BIAFW trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas BIAFW's P/E ratio is N/A. In terms of profitability, A's ROE is +0.20%, compared to BIAFW's ROE of -3.81%. Regarding short-term risk, A is less volatile compared to BIAFW. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check BIAFW's competition here
A vs HTGM Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, A is priced at $111.51, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas HTGM's P/E ratio is -0.03. In terms of profitability, A's ROE is +0.20%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, A is more volatile compared to HTGM. This indicates potentially higher risk in terms of short-term price fluctuations for A.Check HTGM's competition here
A vs BIOC Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, A is priced at $111.51, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas BIOC's P/E ratio is -0.01. In terms of profitability, A's ROE is +0.20%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, A is less volatile compared to BIOC. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check BIOC's competition here
A vs PRENW Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, PRENW has a market cap of 281.1K. Regarding current trading prices, A is priced at $111.51, while PRENW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas PRENW's P/E ratio is N/A. In terms of profitability, A's ROE is +0.20%, compared to PRENW's ROE of -0.36%. Regarding short-term risk, A is less volatile compared to PRENW. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check PRENW's competition here
A vs SQLLW Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, SQLLW has a market cap of 159.3K. Regarding current trading prices, A is priced at $111.51, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas SQLLW's P/E ratio is -0.01. In terms of profitability, A's ROE is +0.20%, compared to SQLLW's ROE of +6.06%. Regarding short-term risk, A is less volatile compared to SQLLW. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check SQLLW's competition here
A vs TTOO Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, TTOO has a market cap of 14K. Regarding current trading prices, A is priced at $111.51, while TTOO trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas TTOO's P/E ratio is -0.02. In terms of profitability, A's ROE is +0.20%, compared to TTOO's ROE of +1.47%. Regarding short-term risk, A is more volatile compared to TTOO. This indicates potentially higher risk in terms of short-term price fluctuations for A.Check TTOO's competition here
A vs BNGOW Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, A is priced at $111.51, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas BNGOW's P/E ratio is N/A. In terms of profitability, A's ROE is +0.20%, compared to BNGOW's ROE of -0.86%. Regarding short-term risk, A is less volatile compared to BNGOW. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check BNGOW's competition here
A vs DHR-PA Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, A is priced at $111.51, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, A's ROE is +0.20%, compared to DHR-PA's ROE of +0.07%. Regarding short-term risk, A is less volatile compared to DHR-PA. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check DHR-PA's competition here
A vs MEUSW Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, A is priced at $111.51, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas MEUSW's P/E ratio is N/A. In terms of profitability, A's ROE is +0.20%, compared to MEUSW's ROE of -5.52%. Regarding short-term risk, A is less volatile compared to MEUSW. This indicates potentially lower risk in terms of short-term price fluctuations for A.Check MEUSW's competition here
A vs OCDX Comparison March 2026
A plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 31.5B. In comparison, OCDX has a market cap of 0. Regarding current trading prices, A is priced at $111.51, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 24.67, whereas OCDX's P/E ratio is -42.28. In terms of profitability, A's ROE is +0.20%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, A is more volatile compared to OCDX. This indicates potentially higher risk in terms of short-term price fluctuations for A.Check OCDX's competition here